549
Views
0
CrossRef citations to date
0
Altmetric
Editorial

The ageing of Cystic Fibrosis patients with new modulators: current gaps and challenges

, , &
Pages 1091-1094 | Received 29 Nov 2023, Accepted 24 Jan 2024, Published online: 12 Feb 2024
 

Abbreviations

CF=

Cystic Fibrosis

CFTR=

Cystic Fibrosis Transmembrane Conductance Regulator

CFTRm=

Cystic Fibrosis Transmembrane Conductance Regulator protein modulator

HEMT=

Highly Effective CFTR Modulator Therapy

ECFSPR=

European Cystic Fibrosis Patient Registry

pwCF=

people with Cystic Fibrosis

FDA=

Food and Drug Administration

EMA=

European Medicines Agency

MHRA=

Medicines and Healthcare products Regulatory Agency

EEUU=

United States

UK=

United Kingdom

EU=

European Union

EC=

European Commission

Declaration of interest

A Felipe Montiel, A Álvarez Fernández and E Polverino have received honoraria from Vertex as speakers. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.